Industry Newstyk2psoriasistakedaphase 3
Takeda Reports Zasocitinib Achieves High Psoriasis Clearance
6.1
Takeda announced Phase 3 results for zasocitinib (TAK-279) at the 2026 AAD meeting showing about 69–71% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16 and significant PASI 75/90/100 improvements versus placebo and apremilast. Safety was consistent with Phase 2b with no new signals, responses deepened through week 24 and remained durable to week 60; Takeda plans NDA submissions starting fiscal 2026.
Key Points
- 1Demonstrates high efficacy: ~70% sPGA 0/1 and substantial PASI90/100 at week 16
- 2Indicates oral TYK2 can deliver rapid, durable clearance, offering a noninjection alternative
- 3Suggests clinicians may gain a convenient oral treatment option pending regulatory approval
Scoring Rationale
Strong, well-powered Phase 3 efficacy with official AAD presentation; limited by clinical focus outside core data-science topics.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
